{"id":43643,"date":"2025-10-17T13:06:36","date_gmt":"2025-10-17T05:06:36","guid":{"rendered":"https:\/\/flcube.com\/?p=43643"},"modified":"2025-10-17T13:06:37","modified_gmt":"2025-10-17T05:06:37","slug":"leads-biolabs-dianthus-therapeutics-announce-global-partnership-for-lbl%e2%80%91047-bispecific-fusion-protein","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43643","title":{"rendered":"Leads\u202fBiolabs, Dianthus\u202fTherapeutics Announce Global Partnership for LBL\u2011047 Bispecific Fusion Protein"},"content":{"rendered":"\n<p><strong>Nanjing Leads Biolabs Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9887:HKG\">HKG: 9887<\/a>) today announced an exclusive global partnership with <strong>Dianthus\u202fTherapeutics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/DNTH:NASDAQ\">NASDAQ: DNTH<\/a>) to jointly advance the novel anti\u2011BDCA2\/TACI bispecific fusion protein <strong>LBL\u2011047<\/strong> (to be marketed as <strong>DNTH212<\/strong> outside Greater China). The collaboration combines Leads Biolabs\u2019 first\u2011in\u2011class, long\u2011acting bispecific platform with Dianthus\u2019 expertise in global development, manufacturing, and commercialization.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-highlights\">Key Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>LBL\u2011047 (DNTH212) \u2013 anti\u2011BDCA2\/TACI bispecific fusion protein<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>U.S. IND clearance granted; IND application accepted in China<\/td><\/tr><tr><td><strong>Strategic Scope<\/strong><\/td><td>Leads Biolabs retains rights in Greater China; Dianthus holds exclusive rights outside Greater China<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Up to <strong>USD\u202f38\u202fmillion<\/strong> in upfront and near\u2011term milestone payments (USD\u202f20\u202fm upfront, USD\u202f5\u202fm Q4\u202f2025, up to USD\u202f13\u202fm milestone). Potential transaction value up to <strong>USD\u202f1\u202fbillion<\/strong><\/td><\/tr><tr><td><strong>Revenue Model<\/strong><\/td><td>Leads Biolabs eligible for tiered royalties (mid\u2011single digits to low double digits) on net sales outside Greater China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-about-lbl-047\">About LBL\u2011047<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action<\/strong> \u2013 Selectively eliminates plasmacytoid dendritic cells (pDCs) to curb Type\u202fI interferon (IFN\u2011I) production while simultaneously inhibiting the BAFF\/APRIL signaling pathway to block B\u2011cell activation, survival, and antibody production.<\/li>\n\n\n\n<li><strong>First\u2011In\u2011Class<\/strong> \u2013 Represents a new therapeutic class of long\u2011acting bispecific fusion proteins targeting BDCA2\/TACI.<\/li>\n\n\n\n<li><strong>Clinical Potential<\/strong> \u2013 Holds promise for autoimmune and inflammatory disorders where pDC\u2011driven IFN\u2011I and BAFF\/APRIL pathways are dysregulated.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Leads Biolabs<\/strong> \u2013 Strengthens its Greater China portfolio and retains control over key intellectual property while monetizing its pre\u2011clinical asset through a lucrative partnership.<\/li>\n\n\n\n<li><strong>Dianthus Therapeutics<\/strong> \u2013 Gains a high\u2011potential asset with a clear regulatory pathway, enabling rapid entry into the global therapeutic landscape.<\/li>\n\n\n\n<li><strong>Patients<\/strong> \u2013 The partnership accelerates access to a potentially disease\u2011modifying therapy for conditions driven by aberrant innate immune activation.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) today announced an exclusive global partnership with Dianthus\u202fTherapeutics&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43645,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,4395,4394,1974,4396],"class_list":["post-43643","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-dianthus-therapeutics","tag-hkg-9887-2","tag-leads-biolabs","tag-nasdaq-dnth"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Leads\u202fBiolabs, Dianthus\u202fTherapeutics Announce Global Partnership for LBL\u2011047 Bispecific Fusion Protein - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) today announced an exclusive global partnership with Dianthus\u202fTherapeutics (NASDAQ: DNTH) to jointly advance the novel anti\u2011BDCA2\/TACI bispecific fusion protein LBL\u2011047 (to be marketed as DNTH212 outside Greater China). The collaboration combines Leads Biolabs\u2019 first\u2011in\u2011class, long\u2011acting bispecific platform with Dianthus\u2019 expertise in global development, manufacturing, and commercialization.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43643\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leads\u202fBiolabs, Dianthus\u202fTherapeutics Announce Global Partnership for LBL\u2011047 Bispecific Fusion Protein\" \/>\n<meta property=\"og:description\" content=\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) today announced an exclusive global partnership with Dianthus\u202fTherapeutics (NASDAQ: DNTH) to jointly advance the novel anti\u2011BDCA2\/TACI bispecific fusion protein LBL\u2011047 (to be marketed as DNTH212 outside Greater China). The collaboration combines Leads Biolabs\u2019 first\u2011in\u2011class, long\u2011acting bispecific platform with Dianthus\u2019 expertise in global development, manufacturing, and commercialization.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43643\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-17T05:06:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-17T05:06:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1701.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43643#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43643\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Leads\u202fBiolabs, Dianthus\u202fTherapeutics Announce Global Partnership for LBL\u2011047 Bispecific Fusion Protein\",\"datePublished\":\"2025-10-17T05:06:36+00:00\",\"dateModified\":\"2025-10-17T05:06:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43643\"},\"wordCount\":324,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43643#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1701.webp\",\"keywords\":[\"Cancer\",\"Dianthus\u202fTherapeutics\",\"HKG: \u202f9887\",\"Leads Biolabs\",\"NASDAQ: DNTH\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43643#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43643\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43643\",\"name\":\"Leads\u202fBiolabs, Dianthus\u202fTherapeutics Announce Global Partnership for LBL\u2011047 Bispecific Fusion Protein - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43643#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43643#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1701.webp\",\"datePublished\":\"2025-10-17T05:06:36+00:00\",\"dateModified\":\"2025-10-17T05:06:37+00:00\",\"description\":\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) today announced an exclusive global partnership with Dianthus\u202fTherapeutics (NASDAQ: DNTH) to jointly advance the novel anti\u2011BDCA2\\\/TACI bispecific fusion protein LBL\u2011047 (to be marketed as DNTH212 outside Greater China). The collaboration combines Leads Biolabs\u2019 first\u2011in\u2011class, long\u2011acting bispecific platform with Dianthus\u2019 expertise in global development, manufacturing, and commercialization.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43643#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43643\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43643#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1701.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1701.webp\",\"width\":1080,\"height\":608,\"caption\":\"Leads\u202fBiolabs, Dianthus\u202fTherapeutics Announce Global Partnership for LBL\u2011047 Bispecific Fusion Protein\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43643#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leads\u202fBiolabs, Dianthus\u202fTherapeutics Announce Global Partnership for LBL\u2011047 Bispecific Fusion Protein\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Leads\u202fBiolabs, Dianthus\u202fTherapeutics Announce Global Partnership for LBL\u2011047 Bispecific Fusion Protein - Insight, China&#039;s Pharmaceutical Industry","description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) today announced an exclusive global partnership with Dianthus\u202fTherapeutics (NASDAQ: DNTH) to jointly advance the novel anti\u2011BDCA2\/TACI bispecific fusion protein LBL\u2011047 (to be marketed as DNTH212 outside Greater China). The collaboration combines Leads Biolabs\u2019 first\u2011in\u2011class, long\u2011acting bispecific platform with Dianthus\u2019 expertise in global development, manufacturing, and commercialization.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43643","og_locale":"en_US","og_type":"article","og_title":"Leads\u202fBiolabs, Dianthus\u202fTherapeutics Announce Global Partnership for LBL\u2011047 Bispecific Fusion Protein","og_description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) today announced an exclusive global partnership with Dianthus\u202fTherapeutics (NASDAQ: DNTH) to jointly advance the novel anti\u2011BDCA2\/TACI bispecific fusion protein LBL\u2011047 (to be marketed as DNTH212 outside Greater China). The collaboration combines Leads Biolabs\u2019 first\u2011in\u2011class, long\u2011acting bispecific platform with Dianthus\u2019 expertise in global development, manufacturing, and commercialization.","og_url":"https:\/\/flcube.com\/?p=43643","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-17T05:06:36+00:00","article_modified_time":"2025-10-17T05:06:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1701.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43643#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43643"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Leads\u202fBiolabs, Dianthus\u202fTherapeutics Announce Global Partnership for LBL\u2011047 Bispecific Fusion Protein","datePublished":"2025-10-17T05:06:36+00:00","dateModified":"2025-10-17T05:06:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43643"},"wordCount":324,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43643#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1701.webp","keywords":["Cancer","Dianthus\u202fTherapeutics","HKG: \u202f9887","Leads Biolabs","NASDAQ: DNTH"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43643#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43643","url":"https:\/\/flcube.com\/?p=43643","name":"Leads\u202fBiolabs, Dianthus\u202fTherapeutics Announce Global Partnership for LBL\u2011047 Bispecific Fusion Protein - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43643#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43643#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1701.webp","datePublished":"2025-10-17T05:06:36+00:00","dateModified":"2025-10-17T05:06:37+00:00","description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) today announced an exclusive global partnership with Dianthus\u202fTherapeutics (NASDAQ: DNTH) to jointly advance the novel anti\u2011BDCA2\/TACI bispecific fusion protein LBL\u2011047 (to be marketed as DNTH212 outside Greater China). The collaboration combines Leads Biolabs\u2019 first\u2011in\u2011class, long\u2011acting bispecific platform with Dianthus\u2019 expertise in global development, manufacturing, and commercialization.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43643#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43643"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43643#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1701.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1701.webp","width":1080,"height":608,"caption":"Leads\u202fBiolabs, Dianthus\u202fTherapeutics Announce Global Partnership for LBL\u2011047 Bispecific Fusion Protein"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43643#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Leads\u202fBiolabs, Dianthus\u202fTherapeutics Announce Global Partnership for LBL\u2011047 Bispecific Fusion Protein"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1701.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43643"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43643\/revisions"}],"predecessor-version":[{"id":43646,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43643\/revisions\/43646"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43645"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}